VectorGene Biotech Limited is a global precision medicine and advanced therapy technology transfer company. We help institutions build local capabilities in genomics, CAR-T manufacturing, cell therapy, gene therapy, and translational biomedical platforms.
VectorGene was founded on a simple observation: most of the world's most important biomedical breakthroughs — precision genomics, CAR-T cell therapy, autologous gene therapy — remain locked inside a small number of high-resource markets. Patients elsewhere either travel overseas at extreme cost, or they go without.
We exist to close that gap. Not by selling technology as a product, but by transferring it as a capability. We work with governments, hospitals, research institutes, and biotechnology partners to design programs that move from concept to facility, from facility to validated clinical service, and from clinical service to sustainable national infrastructure.
Headquartered in Hong Kong, with deep collaborations across Chinese genomic, cellular, and gene therapy ecosystems, VectorGene operates as a partner rather than a vendor — one focused on what local institutions actually need to lead precision medicine in their own countries.
To enable genomic diagnostics, cellular therapies, gene therapies, and international scientific collaborations that improve outcomes for patients with cancer, inherited diseases, and complex medical conditions — through structured technology transfer, local capacity building, and regulatory-aware implementation.
To build a connected network of precision medicine and advanced therapy capability — integrating genomics, cell therapy, gene therapy, clinical research, and local healthcare infrastructure — so that patients worldwide can access advanced diagnostics and next-generation treatments closer to home.
The biotech industry is full of distributors, brokers, and referral agencies. VectorGene was built to do something they cannot — transfer durable scientific capability into local hands.
Our deliverable is local capacity — trained teams, validated workflows, regulatory documentation, working facilities. Not boxes shipped from overseas.
Direct relationships with leading Chinese genomic, cell therapy, and gene therapy institutions — including national-level genome research and specialized hemoglobinopathy programs.
NGS, CAR-T, immune cell therapy, gene therapy, pathogen sequencing, microbiome, and organoid drug screening — under one coordinated implementation framework.
Every program is designed with local validation, ethics review, GMP standards, clinical governance, and quality systems built in — not bolted on later.
Facility planning, SOPs, batch records, training, validation, clinical workflow design, and commercialization — we work through the operational detail, not just the vision.
The point of localization is not just convenience — it is cost reduction. Local capability dramatically reduces dependence on high-cost overseas treatment.
VectorGene does not impose a single playbook on every country. Each partner operates in a different regulatory environment, with different infrastructure, different disease priorities, and different commercial realities. Our approach starts with listening, then designs a program that fits.
VectorGene's partner network spans technology sources, biotechnology developers, clinical institutions, and implementation partners across multiple jurisdictions.
Collaborations with Chinese genomic and cell therapy institutions for international localization of advanced diagnostics, CAR-T manufacturing, and precision medicine services.
Partnerships with specialized Chinese biotechnology companies for hemoglobinopathy gene therapy programs, supporting localization subject to local regulatory approval.
Direct engagement with local healthcare stakeholders to co-design programs that align with national health priorities, regulatory frameworks, and clinical infrastructure.
Operating in advanced therapy and genomics carries a high duty of care. These are non-negotiable principles that shape every VectorGene engagement.
No program proceeds without robust ethics review, clinical governance, adverse event monitoring, and long-term follow-up frameworks in place.
VectorGene supports local regulatory pathways, not workarounds. Every program is designed for the regulatory environment of the host country.
We distinguish between approved therapies, investigational treatments, and early research. We do not market unapproved therapies as standard care.
Cell therapy, gene therapy, and clinical genomics programs require rigorous quality management. We build for that level of discipline from inception.
Partner data, clinical information, and commercial terms are reviewed under strict confidentiality and never shared without explicit written consent.
Success means programs that continue functioning at high quality long after the formal technology transfer phase has ended.
If your institution is exploring technology transfer, clinical implementation, or strategic biotech partnership — we would welcome the conversation.